Skip to main content

AS/Spondyloarthritis

      RT @JulianSegan: Other potential mechanisms for survival selection against the plague via MHC presentation to CD8 T cell
      Other potential mechanisms for survival selection against the plague via MHC presentation to CD8 T cells. May be associated with SpA/HLA B27 @RheumNow @HRheuminations #ACR22 #rheuminations https://t.co/Rv117B4IYp
      RT @RichardPAConway: Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bi
      Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh
      RT @RichardPAConway: Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal prog
      Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4
      RT @RichardPAConway: Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work.
      Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk
      RT @synovialjoints: IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in

      ◦ total spinal pain (SP)
      ◦ nocturnal SP
      IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ◦ total spinal pain (SP) ◦ nocturnal SP ◦ morning stiffness (BASDAI) ◦ fatigue (FACIT-F) Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB #ACR22 @RheumNow
      RT @synovialjoints: JAK and TYK-2 inhibitors and indications in SpA:

      ● Tofacitinib ➣ Pan JAKi (AS, PsA)
      ● Baricit
      JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
      RT @RHEUMarampa: Differences between #uveitis pattern in AS vs. PsA and IBD 👇

      This is always asked to our rheum fell
      2 years ago
      Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
      RT @synovialjoints: Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors,
      Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ